Horizon Pharma (HZNP) Tops Q4 EPS by 13c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil, producer inflation weaken
- Oil falls on weaker demand outlook and higher US stocks
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Horizon Pharma plc (HZNP) Reports Phase 3 Confirmatory Trial Evaluating Teprotumumab (OPTIC) for Treatment of Active Thyroid Eye Disease (TED) Met Primary & All Secondary Endpoints
February 28, 2019 7:22 AM ESTHorizon Pharma plc (NASDAQ: HZNP) today announced topline results from its Phase 3 confirmatory trial evaluating teprotumumab for the treatment of active thyroid eye disease (TED). The study met its primary endpoint, showing more patients treated with teprotumumab compared with placebo had a meaningful... More
Horizon Pharma (HZNP) PT Raised to $26 at Cantor Fitzgerald
February 27, 2019 11:41 AM ESTCantor Fitzgerald analyst Louise Chen raised the price target on Horizon Pharma (NASDAQ: HZNP) to $26.00 (from $23.00) while maintaining a Overweight rating.
Chen commented, "The increase in our PT is driven by upwards earnings revisions. We use a blend of DCF... More
